Publisher
Springer Science and Business Media LLC
Reference115 articles.
1. Abratt RP (1995) Current chemotherapy of advanced non-small cell lung cancer. Anticancer Drugs 6: (Suppl 6) 15–18
2. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1991) Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9: 1618–1626
3. Alberola V, Camps C, Provencia M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado A, Azagra P, Jimenez U, Ganzalez-Larriba JL, Cardenal F, Artal A, Carrato A, Morales S, Sanchez JJ (2001) Cisplatin/Gemcitabine (CG) vs. Cisplatin/Gemcitabine/Vinorelbine (CGV) vs. Sequential Doublets of Gemcitabine/Vinorelbine followed by Ifosfamide/Vinorelbine (GV/IV) in advanced Non-small cell lung cancer (NSCLC): Results of a Spanish Lung Cancer Group Phase III Trial (GEPC/98-02) (abstract). Proc Am Soc Clin Oncol 20: A1229
4. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J (2000) Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer–a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 83: 447–453
5. Bahl A, Falk S (2001) Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know?. Br J Cancer 84: 1143–1145
Cited by
88 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献